ROBERT M. JONES,JUERG LEHMANN,WEICHAO CHEN,JEFFREY EDWARDS,GLEN MARQUEZ,MICHAEL E. MORGAN,ABU J.M. SADEQUE,SUN HEE KIM
申请号：
NI201300030
公开号：
NI201300030A
申请日:
2013.03.18
申请国别(地区):
NI
年份:
2013
代理人:
摘要：
The promoter of gpr119 receiver: 3-fluoro-4 - (5-fluoro-6 - (4 - (3 - (2-fluoropropane-2-il) - 1,2,4-oxadiazol-5-il) piseridin-1-il (pirimidin-4-ilamino) - N, n-dimethylbenzene zamida； 3-fluoro-4 - (5-fluoro-6 - (4 - (3 - (2-fluoro-il) - 1,2), 4-oxadiazol-5-il) piseridin-1-il) - pirimidin-4-ilamin) - n-methylbenzamida； 3-fluoro-4 - (5-fluoro-6 - (4 - (3 - (2-fluoropropan-2-il) - 1,2,4-oxadiazol-5-il) piseridin-1-il) pirimidin-4-ilamino) benzamida, and acceptable salts, solutions and medicinal hydrates of these substances,It is useful as a single drug preparation or in combination with one or more other drug preparations, such as DPP-IV inhibitors, two handed kits, α - glucose inhibitors, similar insulin, flutamide, SGLT2 inhibitors, megletin, thiazolpidan or similar diphenylamine type stimulants, For example, in the treatment of a specific disorder, a disorder related to the gpr119 receptor, a disease improved by increasing the secretion of a foreign body, a disease improved by increasing blood, a disease characterized by low bone mass, a neurological disorder,A metabolic disease, type 2 diabetes, obesity, and related complications.La presente invención se refiere a los agonistas del receptor GPR119: 3 - fluoro - 4 - ( 5 - fluoro - 6 - ( 4 - ( 3 - ( 2 - fluoropropan - 2 - il ) - 1, 2, 4 - oxadiazol - 5 - il ) piperidin - 1 - il ) pirimidin - 4 - ilamino ) - N, N - dimetilbenzamida； 3 - fluoro - 4 - ( 5 - fluoro - 6 - ( 4 - ( 3 - ( 2 - fluoropropan - 2 - il ) - 1, 2, 4 - oxadiazol - 5 - il ) piperidin - 1 - il ) pirimidin - 4 - ilamino) - N -metilbenzamida； y 3 - fluoro - 4 - ( 5 - fluoro - 6 - ( 4 - ( 3 - ( 2 - fluoropropan - 2 - il) - 1, 2, 4 - oxadiazol - 5 - il ) piperidin - 1 - il ) pirimidin - 4 - ilamino ) benzamida, y a sales, solvatos e hidratos farmacéuticamente aceptables de estos, que son útiles como un agente farmacéutico único o combinados con uno o más agentes farmacéuticos adicionales tales como un inhibidor de DPP - IV, una biguanida, un inhibidor de
